Upon the Recommendation by the Protector of Citizens, the National Health Insurance Fund (RFZO) has included on the list of medicines dispensed at the expense of compulsory health insurance the medicines for increasing the level of estrogen necessary to preserve the health of trans women and other women who have low level of estradiol, after 10 years that these were not in circulation.
 

After learning that the medicine for maintaining hormonal status of these three categories of women has not been in circulation since 2012, the Protector of Citizens, upon his own-initiative, requested the RFZO in July 2019 to provide conditions to include the medicines for increasing the level of estrogen estradiol amp. 10 mg и estradiol valerat tbl. 2 mg on the list of medicines dispensed at the expense of compulsory health insurance.
 

In late December 2021, the Central Committee for Medicines notified the Protector of Citizens that the competent authorities completely acted upon the issued opinion with recommendations i.e. that the Commission adopted the Decision to put on List D of the List of Medicines estradiol amp. 10 mg and estradiol valerat tbl. 2 mg for indication suggested by National Expert Committee for Transgender Conditions.
 

The Managing Board of RFZO has adopted an Act with the Decision on including the medicines estradiol amp 10 mg and estradiol valerat tbl. 2 mg on the List D of the medicines, i.e. it adopted the Rulebook on Amendments to the Rulebook on the List of Medicines that are prescribed and dispensed at the expense of compulsory health insurance which, apart from other medicines, puts this medicine as well on the list D of the List of Medicines, stated the Central Committee for Medicines.
 

On 24 November 2021, RFZO submitted to the Ministry of Health the mentioned Rulebook in order to conduct procedure of obtaining the consent of the Government of the Republic of Serbia, added the Central Committee for Medicines.